Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · STANDARD BIOTOOLS INC. (LAB)

Standard BioTools completes sale of Microfluidics business to ARCHIMED

Neutral Impact 3 of 5 m&a Written later

Standard BioTools and ARCHIMED announced on November 3, 2026, that ARCHIMED has completed its acquisition of Standard BioTools' Microfluidics business. The business will operate as a standalone company under the name Biomark Scientific. The filing does not disclose the purchase price or any financial effect on Standard BioTools.

Key points

  • Closing announced November 3, 2026, in a joint press release with ARCHIMED (Exhibit 99.1)
  • Buyer ARCHIMED is an investment firm focused on healthcare industries that manages €15 billion across its funds
  • Business will operate as Biomark Scientific, with Luke Stewart named Chief Commercial Officer
  • The filing gives no purchase price, revenue, or earnings figures for the business

The filing

CompanySTANDARD BIOTOOLS INC. (LAB)
Form8-K, current report
Filed with the SECNov 3, 2026, 8:23 AM ET
Accession number0001140361-26-041705

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.